Robust financial growth for Kiniksa Pharmaceuticals in Q2 2025, including 52% YoY ARCALYST revenue growth & raised guidance.

Synopsys, Inc. (SNPS) is currently at $646.13, up $53.50 or 9.03% --Would be new all-time high (Based on available data back to Feb. 26, 1992) --Would be the first new record closing high since July 5 ...

There's plenty of reason to be optimistic about Synopsys' future; however, whether it could realistically make you a ...